These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15573053)

  • 1. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci.
    Winston LG; Charlebois ED; Pang S; Bangsberg DR; Perdreau-Remington F; Chambers HF
    Am J Infect Control; 2004 Dec; 32(8):462-9. PubMed ID: 15573053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
    Shlaes DM; Baughman R; Boylen CT; Chan JC; Charan NB; Cormier YC; Erickson A; Grossman R; Kirmani N; Suh B
    J Antimicrob Chemother; 1994 Oct; 34(4):565-77. PubMed ID: 7868408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers.
    Stiefel U; Paterson DL; Pultz NJ; Gordon SM; Aron DC; Donskey CJ
    Infect Control Hosp Epidemiol; 2004 May; 25(5):380-3. PubMed ID: 15188842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group.
    Tan JS; Wishnow RM; Talan DA; Duncanson FP; Norden CW
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1580-6. PubMed ID: 8215266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens.
    Paterson DL; Muto CA; Ndirangu M; Linden PK; Potoski BA; Capitano B; Bonomo RA; Aron DC; Donskey CJ
    Antimicrob Agents Chemother; 2008 Feb; 52(2):465-9. PubMed ID: 18025111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract.
    Donskey CJ; Hanrahan JA; Hutton RA; Rice LB
    J Infect Dis; 2000 May; 181(5):1830-3. PubMed ID: 10823795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci.
    Quale J; Landman D; Saurina G; Atwood E; DiTore V; Patel K
    Clin Infect Dis; 1996 Nov; 23(5):1020-5. PubMed ID: 8922796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher risk of neutropenia associated with piperacillin-tazobactam compared with ticarcillin-clavulanate in children.
    Lemieux P; Grégoire JP; Thibeault R; Bergeron L
    Clin Infect Dis; 2015 Jan; 60(2):203-7. PubMed ID: 25301207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit.
    May AK; Melton SM; McGwin G; Cross JM; Moser SA; Rue LW
    Shock; 2000 Sep; 14(3):259-64. PubMed ID: 11028540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.
    File TM; Tan JS
    Eur J Surg Suppl; 1994; (573):51-5. PubMed ID: 7524796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bactericidal activity of combinations of ticarcillin-clavulanic acid or other beta-lactams (amoxicillin, piperacillin-tazobactam, ticarcillin) with gentamicin against Enterococcus faecalis and E. faecium].
    Leclercq R; Duval J
    Pathol Biol (Paris); 1995 Apr; 43(4):245-52. PubMed ID: 7567109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
    Zobell JT; Waters CD; Young DC; Stockmann C; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Feb; 48(2):107-22. PubMed ID: 22949297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enterococci.
    Rice LB; Lakticová V; Helfand MS; Hutton-Thomas R
    J Infect Dis; 2004 Dec; 190(12):2162-6. PubMed ID: 15551215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for vancomycin-resistant Enterococcus colonization in hematologic patients.
    Mioljević V; Marković-Denić L; Vidović A; Jovanović M; Tosić T; Tomin D
    Vojnosanit Pregl; 2013 Dec; 70(12):1109-16. PubMed ID: 24450255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
    DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection and colonization with vancomycin-resistant Enterococcus faecium in an acute care Veterans Affairs Medical Center: a 2-year survey.
    Goetz AM; Rihs JD; Wagener MM; Muder RR
    Am J Infect Control; 1998 Dec; 26(6):558-62. PubMed ID: 9836838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M; Yang Y; Livermore DM
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for prolonged carriage of vancomycin-resistant Enterococcus faecium among patients in intensive care units: a case-control study.
    Yoon YK; Lee SE; Lee J; Kim HJ; Kim JY; Park DW; Sohn JW; Kim MJ
    J Antimicrob Chemother; 2011 Aug; 66(8):1831-8. PubMed ID: 21652622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.